HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for
Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or...
Source: globenewswire.com
Metastatic Head News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Metastatic Head. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Metastatic Head Today - Breaking & Trending Today
NANOBIOTIX Provides Business Update and Reports Full Year
Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel...
Source: globenewswire.com
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV expands worldwide potential of novel radioenhancer NBTXR3Prolonged survival in Study 102 reinforces...
Source: marketscreener.com
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel radioenhancer NBTXR3Prolonged survival in Study 102 reinforces pivotal NANORAY-312 trial design in head and
Source: eagletribune.com
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Upda
- Total Revenues of $480 million for the Fourth Quarter of 2023, $1,830 million for the Fiscal Year 2023 -- Cabozantinib Franchise Achieved $1,629 million in U.S. Net Product Revenues for the Fiscal Year 2023, including $429 million for the Fourth Quarter of 2023 -- GAAP Diluted EPS of $0.27 for the Fourth Quarter o...
Source: pharmiweb.com